Indaptus Therapeutics (INDP) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Indaptus Therapeutics (INDP) over the past year, gaining 166.0% versus a loss of 38.8%. Over five years, PRLD leads with a -76.4% price change compared with -99.0% for INDP. Prelude Therapeutics is the larger company by market cap ($305.6 million vs $301.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDP | PRLD |
|---|---|---|
| Share price | $2.26 | $3.83 |
| Market cap | $301.13M | $305.65M |
| 1-day change | -12.74% | +0.52% |
| YTD return | -22.34% | +32.07% |
| 1-year return | -38.75% | +165.97% |
| 5-year return | -98.97% | -76.45% |
| EPS (TTM) | $-5.37 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.96 | $6.83 |
| 52-week low | $0.92 | $1.15 |
| Distance from 52-week high | -62.08% | -43.92% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +140.21% |
| Average volume | 832.95K | 477.81K |
| Shares outstanding | 133.24M | 65.08M |
| Employees | 5 | 79 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed INDP by 204.7 percentage points over the past year.
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Healthcare · Biotechnology · 5 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Healthcare · Biotechnology · 79 employees
INDP vs PRLD FAQ
Which is bigger, Indaptus Therapeutics or Prelude Therapeutics?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $305.65M compared with $301.13M for Indaptus Therapeutics (INDP).
Which stock has performed better over the past year, INDP or PRLD?
PRLD returned +165.97% over the past 12 months, compared with -38.75% for INDP (price return, excluding dividends). Past performance does not predict future results.
Are Indaptus Therapeutics and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.